Tislelizumab and CAPOX Therapy. NCCP National SACT Regimen. HSE.

Regulatory approval published by the Health Service Executive.

Citation

Tislelizumab and CAPOX Therapy, 2026, version number 1, NCCP National SACT Regimen, NCCP, viewed 02/08/2026, https://healthservice.hse.ie/documents/7463/00924_Tislelizumab_and_CAPOX.pdf

Regulatory approvals

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication	Statements
First-line treatment of adult patients with unresectable, locally advanced or metastatic oesophageal squamous cell carcinoma (OSCC) whose tumours express programmed death-ligand (PD-L1) with a tumour area positivity (TAP) score >= 5%.	1

Therapeutic response

Precision oncology relationships for therapeutic response derived from this document.

Organizations	Biomarkers	Cancer types	Therapies
HSE (1)	PD-L1 (TAP) >= 5%	Esophageal Squamous Cell Carcinoma	Capecitabine, Oxaliplatin, Tislelizumab